Review





Similar Products

gene exp ncoa4 ele1 ret fusion hs04421351 ft  (Thermo Fisher)
94
Thermo Fisher gene exp ncoa4 ele1 ret fusion hs04421351 ft
Gene Exp Ncoa4 Ele1 Ret Fusion Hs04421351 Ft, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp ncoa4 ele1 ret fusion hs04421351 ft/product/Thermo Fisher
Average 94 stars, based on 1 article reviews
gene exp ncoa4 ele1 ret fusion hs04421351 ft - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
ret solution  (TargetMol)
93
TargetMol ret solution
Ret Solution, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ret solution/product/TargetMol
Average 93 stars, based on 1 article reviews
ret solution - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
gene exp ccdc6 ret fusion hs04421293 ft  (Thermo Fisher)
94
Thermo Fisher gene exp ccdc6 ret fusion hs04421293 ft
Gene Exp Ccdc6 Ret Fusion Hs04421293 Ft, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp ccdc6 ret fusion hs04421293 ft/product/Thermo Fisher
Average 94 stars, based on 1 article reviews
gene exp ccdc6 ret fusion hs04421293 ft - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
ret inhibitor pralsetinib  (MedChemExpress)
93
MedChemExpress ret inhibitor pralsetinib
a Forest plot of gene-level odds ratios for peritoneal metastasis across two CRC cohorts. b , c Transcriptional activities of SMAD4 ( b ) and TCF7L2 ( c ) inferred from bulk RNA-seq data in two independent colorectal cancer cohorts. PT, primary tumor; PM, peritoneal metastasis. ** P < 0.01, *** P < 0.001. d <t>RET</t> signature score inferred from bulk RNA-seq data in two independent gastric cancer cohorts. *** P < 0.001. e Representative bright-field images of tumors from control and <t>pralsetinib-treated</t> mice. f Comparison of tumor weight between control and pralsetinib-treated groups. Data are presented as mean ± SEM; statistical significance was determined by a two-tailed Student’s t test. *** P < 0.001. g , h Multivariable analysis of factors associated with tumor progression. Forest plot displays odds ratios for peritoneal metastasis (PM), cancer subtypes, and treatment modalities from a logistic regression model ( g ) or a logistic regression model that incorporated interaction terms between key variables ( h ).
Ret Inhibitor Pralsetinib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ret inhibitor pralsetinib/product/MedChemExpress
Average 93 stars, based on 1 article reviews
ret inhibitor pralsetinib - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
mouse monoclonal antibody  (AMS Biotechnology)
96
AMS Biotechnology mouse monoclonal antibody
a Forest plot of gene-level odds ratios for peritoneal metastasis across two CRC cohorts. b , c Transcriptional activities of SMAD4 ( b ) and TCF7L2 ( c ) inferred from bulk RNA-seq data in two independent colorectal cancer cohorts. PT, primary tumor; PM, peritoneal metastasis. ** P < 0.01, *** P < 0.001. d <t>RET</t> signature score inferred from bulk RNA-seq data in two independent gastric cancer cohorts. *** P < 0.001. e Representative bright-field images of tumors from control and <t>pralsetinib-treated</t> mice. f Comparison of tumor weight between control and pralsetinib-treated groups. Data are presented as mean ± SEM; statistical significance was determined by a two-tailed Student’s t test. *** P < 0.001. g , h Multivariable analysis of factors associated with tumor progression. Forest plot displays odds ratios for peritoneal metastasis (PM), cancer subtypes, and treatment modalities from a logistic regression model ( g ) or a logistic regression model that incorporated interaction terms between key variables ( h ).
Mouse Monoclonal Antibody, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse monoclonal antibody/product/AMS Biotechnology
Average 96 stars, based on 1 article reviews
mouse monoclonal antibody - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
ret ab134100  (Proteintech)
96
Proteintech ret ab134100
a Forest plot of gene-level odds ratios for peritoneal metastasis across two CRC cohorts. b , c Transcriptional activities of SMAD4 ( b ) and TCF7L2 ( c ) inferred from bulk RNA-seq data in two independent colorectal cancer cohorts. PT, primary tumor; PM, peritoneal metastasis. ** P < 0.01, *** P < 0.001. d <t>RET</t> signature score inferred from bulk RNA-seq data in two independent gastric cancer cohorts. *** P < 0.001. e Representative bright-field images of tumors from control and <t>pralsetinib-treated</t> mice. f Comparison of tumor weight between control and pralsetinib-treated groups. Data are presented as mean ± SEM; statistical significance was determined by a two-tailed Student’s t test. *** P < 0.001. g , h Multivariable analysis of factors associated with tumor progression. Forest plot displays odds ratios for peritoneal metastasis (PM), cancer subtypes, and treatment modalities from a logistic regression model ( g ) or a logistic regression model that incorporated interaction terms between key variables ( h ).
Ret Ab134100, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ret ab134100/product/Proteintech
Average 96 stars, based on 1 article reviews
ret ab134100 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
mouse monoclonal antibody anti hs  (AMS Biotechnology)
96
AMS Biotechnology mouse monoclonal antibody anti hs
a Forest plot of gene-level odds ratios for peritoneal metastasis across two CRC cohorts. b , c Transcriptional activities of SMAD4 ( b ) and TCF7L2 ( c ) inferred from bulk RNA-seq data in two independent colorectal cancer cohorts. PT, primary tumor; PM, peritoneal metastasis. ** P < 0.01, *** P < 0.001. d <t>RET</t> signature score inferred from bulk RNA-seq data in two independent gastric cancer cohorts. *** P < 0.001. e Representative bright-field images of tumors from control and <t>pralsetinib-treated</t> mice. f Comparison of tumor weight between control and pralsetinib-treated groups. Data are presented as mean ± SEM; statistical significance was determined by a two-tailed Student’s t test. *** P < 0.001. g , h Multivariable analysis of factors associated with tumor progression. Forest plot displays odds ratios for peritoneal metastasis (PM), cancer subtypes, and treatment modalities from a logistic regression model ( g ) or a logistic regression model that incorporated interaction terms between key variables ( h ).
Mouse Monoclonal Antibody Anti Hs, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse monoclonal antibody anti hs/product/AMS Biotechnology
Average 96 stars, based on 1 article reviews
mouse monoclonal antibody anti hs - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

Image Search Results


a Forest plot of gene-level odds ratios for peritoneal metastasis across two CRC cohorts. b , c Transcriptional activities of SMAD4 ( b ) and TCF7L2 ( c ) inferred from bulk RNA-seq data in two independent colorectal cancer cohorts. PT, primary tumor; PM, peritoneal metastasis. ** P < 0.01, *** P < 0.001. d RET signature score inferred from bulk RNA-seq data in two independent gastric cancer cohorts. *** P < 0.001. e Representative bright-field images of tumors from control and pralsetinib-treated mice. f Comparison of tumor weight between control and pralsetinib-treated groups. Data are presented as mean ± SEM; statistical significance was determined by a two-tailed Student’s t test. *** P < 0.001. g , h Multivariable analysis of factors associated with tumor progression. Forest plot displays odds ratios for peritoneal metastasis (PM), cancer subtypes, and treatment modalities from a logistic regression model ( g ) or a logistic regression model that incorporated interaction terms between key variables ( h ).

Journal: NPJ Precision Oncology

Article Title: Pan-cancer clinicopathological and genomic characteristics of peritoneal metastasis

doi: 10.1038/s41698-025-01227-7

Figure Lengend Snippet: a Forest plot of gene-level odds ratios for peritoneal metastasis across two CRC cohorts. b , c Transcriptional activities of SMAD4 ( b ) and TCF7L2 ( c ) inferred from bulk RNA-seq data in two independent colorectal cancer cohorts. PT, primary tumor; PM, peritoneal metastasis. ** P < 0.01, *** P < 0.001. d RET signature score inferred from bulk RNA-seq data in two independent gastric cancer cohorts. *** P < 0.001. e Representative bright-field images of tumors from control and pralsetinib-treated mice. f Comparison of tumor weight between control and pralsetinib-treated groups. Data are presented as mean ± SEM; statistical significance was determined by a two-tailed Student’s t test. *** P < 0.001. g , h Multivariable analysis of factors associated with tumor progression. Forest plot displays odds ratios for peritoneal metastasis (PM), cancer subtypes, and treatment modalities from a logistic regression model ( g ) or a logistic regression model that incorporated interaction terms between key variables ( h ).

Article Snippet: The RET inhibitor pralsetinib, which is clinically used, was obtained from MedChemExpress (Cat. No. HY-112301).

Techniques: RNA Sequencing, Control, Comparison, Two Tailed Test